Omeros Corp. (Omeros (OMER)) had a rough Tuesday. The biotech reported mixed third-quarter 2026 results, and investors focused on the misses. Adjusted earnings came in at 6 cents per share, beating the consensus estimate of 3 cents. But revenue reached $35.93 million, falling short of the $37.27 million consensus. The stock was down 17.81% at $13.71 at the time of publication, with trading volume hitting 2.57 million shares, about 65.5% above the 100-day average of 1.55 million shares, according to market data.
Omeros Stock Slips 18%: Mixed Q3, Yartemlea Growth and a European Roadblock
Get Omeros Alerts
Weekly insights + SMS alerts
The Numbers Behind the Quarter
Omeros reported a net loss of $57.4 million, or 79 cents per share, compared with a net loss of $30.9 million, or 47 cents per share, a year earlier. That wider loss included a noncash loss of $62 million, primarily related to mark-to-market adjustments of a derivative associated with unsecured convertible notes due in 2029. Adjusted net income rose to $4.7 million, or 6 cents per share, from $1.8 million, or 2 cents per share, in the second quarter. Operating income reached $4.5 million, compared with an operating loss of $26.4 million a year earlier. The company ended September with $95.3 million in cash and short-term investments and generated $13.3 million in positive operating cash flow during the quarter.
Omeros also took steps to clean up its balance sheet. It repurchased $30.5 million in principal amount of its 2029 convertible notes for $60.2 million, excluding accrued interest. That reduced the outstanding principal to approximately $40.3 million and eliminated $8.6 million in scheduled interest payments. Together with earlier stock repurchases, the transactions reduced the number of outstanding or potentially issuable shares by approximately 5.8 million year to date.
Yartemlea Keeps Growing
Yartemlea (narsoplimab-wuug) is the first and only approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a potentially fatal complication of stem cell transplantation. The drug continues to generate sequential revenue growth. Gross revenue increased 30% to $41.8 million in the third quarter from $32.2 million in the second quarter. Net revenue rose 26% to $35.9 million from $28.5 million in the prior quarter. However, the gross-to-net adjustment increased to 14% from 11.5%. The company attributed the higher adjustment to increased purchases by entities covered by the 340B Drug Pricing Program, reflecting broader customer adoption and increased outpatient use.
Yartemlea's New Technology Add-on Payment designation took effect Oct. 1. Eligible hospitals can receive up to $287,079 in additional Medicare reimbursement per eligible inpatient case involving the drug.
Expanding the Clinical Playbook
Omeros expects to support two investigator-initiated or company co-sponsored studies evaluating Yartemlea. One study will evaluate the drug in patients with hyperinflammatory acute respiratory distress syndrome. The other will assess its ability to prevent TA-TMA in high-risk pediatric transplant patients. Both open-label, single-arm studies will use historical controls. Each study aims to enroll approximately 50 to 60 patients. Omeros expects the studies to begin in late 2026 or early 2027, subject to institutional review board and ethics committee approvals. The company is also exploring additional applications for Yartemlea in conditions involving blood vessel damage, lectin pathway activation or inflammation associated with blood clotting.
Novo Nordisk Collaboration
Omeros said Novo Nordisk A/S (Novo Nordisk (NVO)) remains on track to initiate a Phase 3 trial of zaltenibart, an antibody it acquired from Omeros in 2025. Omeros remains eligible for more than $1.8 billion in development and commercial milestone payments, including up to $100 million in near-term payments, plus tiered royalties on net sales.
European Setback
In October, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opinion on Omeros' application to market narsoplimab for TA-TMA. The decision followed a re-examination of the committee's original negative opinion in June. European regulators previously raised concerns about the study design, insufficient evidence of the drug's effectiveness and limited pediatric data. Omeros also announced plans in October to end its compassionate-use program amid rising U.S. demand. The company is working to provide fully reimbursed, named-patient access in Europe and other regions where permitted. Meanwhile, the U.S. Food and Drug Administration approved Yartemlea in December 2025 to treat TA-TMA in adults and children ages 2 and older.
More News

Dow Drops 1.4% as Salesforce Leads Software Wreck Ahead of Anthropic's Mega IPO

NVIDIA's Jensen Huang Crisis Could Rewrite the Rules of the AI Boom

Wall Street Swaps Chips for Chicken: Staples Are Crushing Tech Like It's 2001

David Tepper Dumps 46% of Alphabet and Bets $172M on Oracle's AI Debt Story

Bitcoin Near $64,000 Is an 'Attractive Entry Point,' Grayscale Says After Brutal Two Weeks

Home Depot Hands the Keys to Its CFO as Profit Outlook Gets Trimmed

Fed Warns Leveraged ETFs Could Supercharge Selloffs as South Koreans Bet $3.8B on SOXL

AMD Stock Rises as NVIDIA's Leadership Shakeup Could Hand It a Big AI Opening
Get Omeros Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all news
Dow Drops 1.4% as Salesforce Leads Software Wreck Ahead of Anthropic's Mega IPO

NVIDIA's Jensen Huang Crisis Could Rewrite the Rules of the AI Boom

Wall Street Swaps Chips for Chicken: Staples Are Crushing Tech Like It's 2001

David Tepper Dumps 46% of Alphabet and Bets $172M on Oracle's AI Debt Story

Bitcoin Near $64,000 Is an 'Attractive Entry Point,' Grayscale Says After Brutal Two Weeks

Home Depot Hands the Keys to Its CFO as Profit Outlook Gets Trimmed

Fed Warns Leveraged ETFs Could Supercharge Selloffs as South Koreans Bet $3.8B on SOXL






